Precision in cancer care increasingly relies on the integration of advanced imaging techniques to guide treatment and monitor outcomes. Imaging-Guided Therapy & Response Assessment enables clinicians to visualize tumors in real time, facilitating targeted interventions such as surgery, radiation therapy, and minimally invasive procedures. Techniques including CT, MRI, PET, and hybrid imaging modalities provide detailed anatomical, functional, and metabolic information, allowing for accurate tumor localization and treatment planning. By leveraging imaging data, healthcare teams can minimize collateral damage to healthy tissue, optimize therapeutic delivery, and enhance overall treatment efficacy. This approach is particularly crucial in complex or hard-to-reach tumors, where precision directly affects patient prognosis and long-term outcomes.
In addition, Imaging-Guided Therapy & Response Assessment supports dynamic evaluation of treatment response and early detection of disease progression. Functional and molecular imaging can reveal metabolic and microenvironmental changes before they are visible through traditional anatomical methods. Incorporating imaging biomarkers and standardized response criteria allows clinicians to adjust therapy in real time, refine risk stratification, and tailor treatment strategies to individual patient needs. By combining advanced imaging with multidisciplinary collaboration, imaging-guided therapy and response assessment strengthen precision oncology, enabling adaptive, personalized interventions that maximize therapeutic effectiveness while minimizing adverse effects and improving overall patient care.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Spatial multi-omics inference of diabetes-triggered pancreatic cancer growth: The key role of cholesterol-induced neutrophil extracellular
Guanqun Li, The First Affiliated Hospital of Harbin Medical University, China
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Multiplexed biosensor detection of cancer biomarkers
Michael Thompson, University of Toronto, Canada